Results 201 to 210 of about 29,074 (242)

Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy. [PDF]

Cell Rep Med
Chen D, Xu R, Ye X, Xiao Y, Wang M, Li W, Luo F, Niu X, Yang X, Su Y, Zeng W, Liu Y, Shang W, Li Y, Zhao X, Hu J, Chen X, Zhu X, Sui X, Gao Y.   +19 more
europepmc   +1 more source

Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives. [PDF]

Front Immunol
Lopatnikova JA, Sennikov SV.
europepmc   +1 more source

Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database. [PDF]

J Immunother Cancer
Li L, Ren F, Liu Z, Tian X, Zhang H, Wang G, Zhang S, Ma L.   +7 more
europepmc   +1 more source

Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches. [PDF]

Antibodies (Basel)
Godugu D, Gattu K, Suri P, Daartey AB, Jadhav K, Rojekar S.   +5 more
europepmc   +1 more source

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

HemaSphere, Volume 10, Issue 3, March 2026.
Morgane Brocard, Damien Roos‐Weil, Lukshe Kanagaratnam, Thomas Hueso, Lucile Bussot, Benjamin Papoular, Cécile Tomowiak, Steeve Chevreux, Gilles Crochet, Tristan Vaugeois, Elise Toussaint, Simone Ferrero, Charalampia Kyriakou, Anne Quinquenel, Prashant Kapoor, Eric Durot   +15 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire   +2 more sources